A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma

Successful long-term control with lamivu

Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: Experience of 2 cases

✍ Masashi Nakagawa; Yoshifumi Simizu; Masaki Suemura; Bunzo Sato 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## Abstract It is well documented that cytotoxic treatment in patients carrying the hepatitis B virus (HBV) enhances the risk of severe hepatic damage. Recently lamivudine has been reported to be effective in suppressing the replication of HBV under such conditions. Here we report two cases with HB